NO2462158T3 - - Google Patents

Info

Publication number
NO2462158T3
NO2462158T3 NO10740823A NO10740823A NO2462158T3 NO 2462158 T3 NO2462158 T3 NO 2462158T3 NO 10740823 A NO10740823 A NO 10740823A NO 10740823 A NO10740823 A NO 10740823A NO 2462158 T3 NO2462158 T3 NO 2462158T3
Authority
NO
Norway
Application number
NO10740823A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2462158(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2462158T3 publication Critical patent/NO2462158T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO10740823A 2009-08-06 2010-08-06 NO2462158T3 (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23181109P 2009-08-06 2009-08-06
PCT/US2010/044760 WO2011031397A1 (en) 2009-08-06 2010-08-06 Method to improve virus removal in protein purification

Publications (1)

Publication Number Publication Date
NO2462158T3 true NO2462158T3 (OSRAM) 2018-06-09

Family

ID=42985499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10740823A NO2462158T3 (OSRAM) 2009-08-06 2010-08-06

Country Status (25)

Country Link
US (5) US10662237B2 (OSRAM)
EP (3) EP4559926A3 (OSRAM)
JP (6) JP2013501075A (OSRAM)
KR (3) KR20180035936A (OSRAM)
CN (2) CN102712691A (OSRAM)
AU (1) AU2010292897B2 (OSRAM)
BR (1) BR112012002574A2 (OSRAM)
CA (1) CA2770235C (OSRAM)
DK (1) DK2462158T3 (OSRAM)
ES (1) ES2662529T3 (OSRAM)
HR (1) HRP20180309T1 (OSRAM)
HU (1) HUE038451T2 (OSRAM)
IL (3) IL217740B (OSRAM)
LT (1) LT2462158T (OSRAM)
MX (1) MX346115B (OSRAM)
MY (1) MY188566A (OSRAM)
NO (1) NO2462158T3 (OSRAM)
NZ (1) NZ597809A (OSRAM)
PL (1) PL2462158T3 (OSRAM)
PT (1) PT2462158T (OSRAM)
RU (1) RU2573894C2 (OSRAM)
SG (1) SG178276A1 (OSRAM)
SI (1) SI2462158T1 (OSRAM)
WO (1) WO2011031397A1 (OSRAM)
ZA (1) ZA201200626B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527425A1 (en) 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
NO2462158T3 (OSRAM) 2009-08-06 2018-06-09
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2830640A1 (en) * 2011-03-25 2012-10-04 Genentech, Inc. Novel protein purification methods
DE102011105525B4 (de) 2011-06-24 2015-03-26 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Biopolymer-Aggregaten und Viren aus einem Fluid
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
HRP20181846T1 (hr) 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
KR102260855B1 (ko) 2013-09-13 2021-06-04 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
AU2015334455B2 (en) * 2014-10-21 2020-05-21 Gennova Biopharmaceuticals Limited A novel purification process for isolation and commercial production of recombinant TNK-tPA (Tenecteplase)
EP3274359B1 (en) * 2015-03-23 2022-11-02 Alexion Pharmaceuticals, Inc. Virus filtration
EP3639911B1 (en) * 2017-06-12 2024-07-31 Asahi Kasei Medical Co., Ltd. Filtration method for protein-containing liquid
KR102753090B1 (ko) * 2017-12-21 2025-01-14 젠자임 코포레이션 단백질 a 크로마토그래피 동안 불순물의 향상된 제거를 위한 방법
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
EP0397687B1 (en) 1987-12-21 1994-05-11 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH02198687A (ja) 1989-01-26 1990-08-07 Asahi Chem Ind Co Ltd 純水の製造方法
JPH038759A (ja) 1989-03-16 1991-01-16 Sumitomo Metal Ind Ltd 半導体磁器物質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
CN1130353A (zh) * 1993-07-09 1996-09-04 史密丝克莱恩比彻姆公司 蛋白质的纯化
HU218159B (hu) * 1993-09-21 2000-06-28 Hemosol Inc. Kiszorításos kromatográfiás eljárás tisztított hemoglobintermék előállítására
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
JP3415222B2 (ja) 1993-10-20 2003-06-09 東洋濾紙株式会社 エンドトキシン吸着能を有するポリエーテルサルホン又はスルホン化ポリエーテルサルホン微孔膜
JP3453623B2 (ja) 1994-03-30 2003-10-06 サンスター株式会社 エンドトキシン吸着除去剤および除去方法
DE69520042T2 (de) 1994-07-28 2001-07-19 Millipore Corp., Bedford Porösesverbundmembran und verfahren
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
ES2195112T5 (es) 1996-02-06 2015-10-15 Roche Diagnostics Gmbh Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo
TW505655B (en) 1997-10-14 2002-10-11 Tanox Inc Enhanced aggregate removal from bulk-biologicals using ion exchange chromatography
GB9907553D0 (en) * 1999-04-01 1999-05-26 Cantab Pharma Res Purification of biological preparations
ES2267552T3 (es) 1999-07-30 2007-03-16 Genentech, Inc. Membranas de filtracion cargadas y sus usos.
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
AU2003272368C1 (en) 2002-09-13 2009-07-23 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
US20040116676A1 (en) 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
EP1403274A1 (en) 2002-09-30 2004-03-31 Meristem Therapeutics Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
US20060257972A1 (en) 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
IN2009KN02655A (OSRAM) * 2003-12-10 2015-10-23 Medarex Inc
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
BRPI0507298A (pt) 2004-01-30 2007-07-03 Suomen Punainen Risti Veripalv processo para a produção de imunoglobulina segura a vìrus
US7390403B2 (en) 2004-03-19 2008-06-24 Millipore Corporation Prefilter system for biological systems
US7776821B2 (en) 2004-10-21 2010-08-17 Statens Serum Institut Method comprising nanofiltration to obtain an MBL product safe from infectious agents and the product obtainable by this method
EP1858928A2 (en) * 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Anti-m-csf antibody compositions having reduced levels of endotoxin
JP2009530378A (ja) * 2006-03-20 2009-08-27 メダレックス インコーポレーティッド タンパク質精製法
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2009017491A1 (en) * 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
WO2008025747A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20080132688A1 (en) 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
SI2087002T1 (sl) 2006-10-27 2014-11-28 Lpath, Inc. Sestavki in postopki za vezavo sfingozin-1-fosfata
WO2008073620A2 (en) 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
SI2078071T1 (sl) 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
TWI601823B (zh) 2007-04-26 2017-10-11 中外製藥股份有限公司 Cell culture methods using media containing high concentrations of amino acids
AU2008343347A1 (en) 2007-12-21 2009-07-09 Genentech, Inc. Crystallization of anti-CD20 antibodies
EP2281000A2 (en) 2008-05-15 2011-02-09 Novo Nordisk A/S Antibody purification process
US9056896B2 (en) * 2009-03-27 2015-06-16 Asahi Kasei Medical Co., Ltd. Method for removing viruses from high concentration monoclonal antibody solution
SG176256A1 (en) 2009-05-27 2012-01-30 Baxter Int A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
NO2462158T3 (OSRAM) 2009-08-06 2018-06-09
CN108409829A (zh) 2009-09-01 2018-08-17 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化

Also Published As

Publication number Publication date
PL2462158T3 (pl) 2018-05-30
IL273486A (en) 2020-05-31
EP4559926A3 (en) 2025-08-06
JP2023029853A (ja) 2023-03-07
HUE038451T2 (hu) 2018-10-29
MX346115B (es) 2017-03-08
IL273486B (en) 2022-04-01
RU2012108318A (ru) 2013-09-20
US10662237B2 (en) 2020-05-26
LT2462158T (lt) 2018-03-26
AU2010292897B2 (en) 2016-01-07
EP2462158B1 (en) 2018-01-10
CN106905413A (zh) 2017-06-30
JP2025003999A (ja) 2025-01-14
KR20130051431A (ko) 2013-05-20
IL217740B (en) 2020-04-30
EP3309168A1 (en) 2018-04-18
ES2662529T3 (es) 2018-04-06
JP2013501075A (ja) 2013-01-10
KR20190018041A (ko) 2019-02-20
IL287431A (en) 2021-12-01
EP4559926A2 (en) 2025-05-28
JP2017206529A (ja) 2017-11-24
CA2770235C (en) 2021-06-29
MX2012001659A (es) 2012-04-30
IL217740A0 (en) 2012-03-29
US20220306726A1 (en) 2022-09-29
US20240083980A1 (en) 2024-03-14
PT2462158T (pt) 2018-02-23
EP2462158A1 (en) 2012-06-13
CA2770235A1 (en) 2011-03-17
MY188566A (en) 2021-12-22
WO2011031397A1 (en) 2011-03-17
NZ597809A (en) 2014-05-30
SG178276A1 (en) 2012-03-29
US11225513B2 (en) 2022-01-18
US20110034674A1 (en) 2011-02-10
KR101844859B1 (ko) 2018-05-18
SI2462158T1 (en) 2018-04-30
KR20180035936A (ko) 2018-04-06
JP2020023491A (ja) 2020-02-13
HRP20180309T1 (hr) 2018-03-23
ZA201200626B (en) 2013-06-26
DK2462158T3 (en) 2018-03-05
AU2010292897A1 (en) 2012-02-16
US20250282850A1 (en) 2025-09-11
JP2016106096A (ja) 2016-06-16
CN102712691A (zh) 2012-10-03
US20200347118A1 (en) 2020-11-05
RU2573894C2 (ru) 2016-01-27
BR112012002574A2 (pt) 2020-11-03

Similar Documents

Publication Publication Date Title
BRPI0925311A2 (OSRAM)
BR112012008195A2 (OSRAM)
BR112012003062A2 (OSRAM)
BRPI0924307A2 (OSRAM)
BR112012008267A2 (OSRAM)
BR122021004633A2 (OSRAM)
BR112012000665A2 (OSRAM)
BR112012003080A2 (OSRAM)
BR122017024704A2 (OSRAM)
BR112012003853A2 (OSRAM)
BR112012012080A2 (OSRAM)
BRPI0924534A2 (OSRAM)
BR112012007656A2 (OSRAM)
BR112012001263A2 (OSRAM)
BR122019005883A2 (OSRAM)
BR112012014856A2 (OSRAM)
BR112012002627A2 (OSRAM)
BR112012007654A2 (OSRAM)
BR112012007672A2 (OSRAM)
BR112012005951A2 (OSRAM)
NO2462158T3 (OSRAM)
BR112012007671A2 (OSRAM)
BR122017013721A2 (OSRAM)
BRPI0924617A2 (OSRAM)
BRPI0925022A2 (OSRAM)